ALSTON & BIRD LLP for BIOMERIEUX, INC.
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
H.R.1, One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of US Tax Code. Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics.
Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH BODDICKER | — |
| EVAN COLLIER | — |
| ALEXANDER GRAF | — |
| JONATHAN JAGODA | — |
| JAMES PATRICK PALUSKIEWICZ | — |
| MARK RAYDER | — |
Health Issues HCR
Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment (per Section 216 of Protecting Access to Medicare Act (PAMA)).
Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEXANDER GRAF | — |
| JOYCE E GRESKO | — |
| JONATHAN JAGODA | — |
| JAMES PATRICK PALUSKIEWICZ | — |
| MARK RAYDER | — |
Medical/Disease Research/Clinical Labs MED
Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment (per Section 216 of Protecting Access to Medicare Act (PAMA)).
Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEXANDER GRAF | — |
| JOYCE E GRESKO | — |
| JONATHAN JAGODA | — |
| JAMES PATRICK PALUSKIEWICZ | — |
| MARK RAYDER | — |
Medicare/Medicaid MMM
Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment (per Section 216 of Protecting Access to Medicare Act (PAMA)).
Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALEXANDER GRAF | — |
| JOYCE E GRESKO | — |
| JONATHAN JAGODA | — |
| JAMES PATRICK PALUSKIEWICZ | — |
| MARK RAYDER | — |
Trade (domestic/foreign) TRD
Discussions regarding tariff proposals.
Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH BODDICKER | — |
| EVAN COLLIER | — |
| JONATHAN JAGODA | — |
| MARK RAYDER | — |
Taxation/Internal Revenue Code TAX
H.R.1, One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of US Tax Code.
Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH BODDICKER | — |
| EVAN COLLIER | — |
| MARK RAYDER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.